PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PNEUMONIA, PRIMARY ATYPICAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1982

[Clinical use of acetylspiramycin for primary atypical pneumonia in the field of pediatrics].

Thirty-one patients with primary atypical pneumonia (16 patients diagnosed as Mycoplasma pneumonia) who visited our Department of Pediatrics between March and December, 1981 were treated with 200 mg tablets of acetylspiramycin. Clinical effects were studied, and the results were as follows. 1. Acetylspriramycin, in principle 30 mg/kg/day, was given to 31 patients with primary atypical pneumonia. The effective rate was 87.1%. (As for the patients with Mycoplasma pneumonia, the effective rate was 93.8%). 2. There was 1 ineffective case and it was judged as a case of other viral pneumonia by the results of clinical laboratory tests. 3. The only side effect observed was eruption which occurred on the 6th day of administration in 1 case and disappeared after the change of administration. From the above results, acetylspiramycin is thought to be an effective antibiotic on primary atypical pneumonia.

Adolescent↗
PubMed1976

The treatment of primary atypical pneumonia with intravenous doxycycline: a report of clinical observations.

Seventeen cases of primary atypical pneumonia which were probably caused by Mycoplasma pneumoniae were studied as in-patients in hospital. All of these patients were treated with intravenous doxycycline and responded quickly to therapy. It has been shown that approximately 30-50% of the cases with primary atypical pneumonia are caused by M. pneumoniae. The remainder of the cases are caused by either viruses or possibly rickettsiae.

Adult↗
PubMed1981

[Clinical effect of acetylspiramycin on primary atypical pneumonia in children (author's transl)].

Clinical effect of acetylspiramycin, one of macrolide antibiotics, primary atypical pneumonia and serologically proven Mycoplasma pneumonia in children was studied. Twenty-four cases of these pneumonia (PAP 11, MP 13) in children were selected and acetylspiramycin was given in dose of approximately 30 mg/kg/day orally. Clinical response was evaluated in terms of improvement in fever, cough and chest X-ray. Clinical response was excellent in 4, good in 5, fair in 14 cases and none in 1 case. No definite adverse effect was observed, however 3 cases showed skin rashes. Two cases showed evanescent small erythematopapulous rash and 1 case developed urticaria on the 2nd to 4th day after this drug was given. These skin rash seemed one of the manifestation of Mycoplasma infections, rather than adverse side effect. One case showed elevated transaminase activity before acetylspiramycin was given and improved on the 2nd week, although this drug was continued. No other side effect was observed. We were able to use acetylspiramycin only in the form of 200 mg tablet and difficulty of the administration was encountered in children under 5 years of age. Other form (dry syrup, etc.) of this drug should be considered for the clinical use in children. In conclusion, acetylspiramycin was effective and safe for the treatment of primary atypical pneumonia and Mycoplasma pneumonia.

Adolescent↗